Literature DB >> 27842315

Randomized Trial to Compare Renal Function and Ductal Response between Indomethacin and Ibuprofen Treatment in Extremely Low Birth Weight Infants.

Yuh Jyh Lin1, Chung Ming Chen, Virender K Rehan, Adrian Florens, Shou Yien Wu, Min Luen Tsai, Yung T Kuo, Fu Kuei Huang, Tsu F Yeh.   

Abstract

BACKGROUND: A head to head comparison study on renal function and ductal response between indomethacin and ibuprofen has rarely been conducted in extremely low birth weight (ELBW) infants.
OBJECTIVES: The aim was to compare renal function and ductal response between indomethacin and ibuprofen in ELBW infants.
METHODS: We performed a double-blind randomized control trial to compare renal function and ductal response between indomethacin (0.2, 0.1, and 0.1 mg/kg i.v. every 24 h for 3 doses) and ibuprofen lysine (10, 5, and 5 mg/kg i.v. every 24 h for 3 doses) in ELBW infants with significant hemodynamic patent ductus arteriosus (cardiovascular dysfunction score >3 and LA/AO ratio ≥1.3).
RESULTS: A total of 144 infants were enrolled: 73 received indomethacin and 71 received ibuprofen lysine. Significant decreases in urine output were seen in 30 infants (41%) in the indomethacin group and 15 (21%) in the ibuprofen group (p = 0.02). The indomethacin group was associated with a significantly higher chance of persistent ductal response than the ibuprofen group (66 vs. 49%, p = 0.046), but with a lower glomerular filtration rate on day 1, higher serum creatinine on days 1, 2, and 7, and lower urinary prostaglandin on days 2-7. Both groups were comparable in mortality and in bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity morbidity.
CONCLUSIONS: With the current dosage, ibuprofen had fewer renal side effects but was associated with a lower rate of persistent ductal closure in ELBW infants. The precise role of prostaglandin on renal tubular function in ELBW infants remains to be further investigated.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27842315     DOI: 10.1159/000450822

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  6 in total

1.  Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen.

Authors:  S Cristea; K Allegaert; A C Falcao; F Falcao; R Silva; A Smits; C A J Knibbe; E H J Krekels
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.

Authors:  Ramesh Vidavalur
Journal:  Paediatr Drugs       Date:  2022-03-01       Impact factor: 3.022

Review 3.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

4.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

Review 5.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2018-09-28

6.  Incidence, risk and risk factors for acute kidney injury associated with the use of intravenous indomethacin in neonatal patent ductus arteriosus: A 16-year retrospective cohort study.

Authors:  Thitinun Raknoo; Waricha Janjindamai; Sirima Sitaruno; Supaporn Dissaneevate; Chaveewan Ratanajamit
Journal:  Pharm Pract (Granada)       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.